Figure 3: Blood vessels from patient group 2 are shown. Examples shown in Figure 3a and f were exclusively seen in this patient group. (a): The morphology of vessels does not appear to be altered after treatment with bevacizumab. However, the lumina of vessels are densely filled with electron opaque material (asterisk) one day after treatment with bevacizumab. Vessels with unusually high and more normal plasma density were localized close to each other (compare Figure 3a and b). (b): The lumen of this vessel shows normal density of plasma (asterisk). It contains two white blood cells with pseudopodia (arrows) 1 day after treatment with bevacizumab. This vessel was localized close to that shown in Figure 3a. (c): A capillary, one day after injection with bevacizumab, with many microvilli-like projections. These form a labyrinth-like structure which nearly closes the vessels lumen (asterisk). This vessel type was frequently observed independent of treatment (see also Figure 2b). (d): The remaining lumen (asterisk) of a capillary as shown in Figure 3c. The endothelial wall has open connections towards the interstitial space (arrowheads). (e): An unstable aggregate of thrombocytes (t) in a neovascular vessel. This is from a patient treated with bevacizumab one day before the CNV was excised. (f): A neovascular vessel closed by thrombotic material (asterisk). One thrombocyte (t) is still not completely degranulated. The patient was treated with bevacizumab one day before the CNV was excised.